4D Molecular Therapeutics FDMT Stock
4D Molecular Therapeutics Price Chart
4D Molecular Therapeutics FDMT Financial and Trading Overview
| 4D Molecular Therapeutics stock price | 12.23 USD |
| Previous Close | 12.12 USD |
| Open | 11.66 USD |
| Bid | 10 USD x 300 |
| Ask | 14.27 USD x 200 |
| Day's Range | 10.98 - 12.37 USD |
| 52 Week Range | 6.96 - 16.93 USD |
| Volume | 813.8K USD |
| Avg. Volume | 1.07M USD |
| Market Cap | 675.64M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.09 USD |
FDMT Valuation Measures
| Enterprise Value | 420.94M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.9844553 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.033193 |
| Price/Book (mrq) | 1.6565082 |
| Enterprise Value/Revenue | 4.382 |
| Enterprise Value/EBITDA | -2.014 |
Trading Information
4D Molecular Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 12.27% |
| S&P500 52-Week Change | 12.28% |
| 52 Week High | 16.93 USD |
| 52 Week Low | 6.96 USD |
| 50-Day Moving Average | 13.19 USD |
| 200-Day Moving Average | 11.06 USD |
FDMT Share Statistics
| Avg. Volume (3 month) | 1.07M USD |
| Avg. Daily Volume (10-Days) | 920.49K USD |
| Shares Outstanding | 55.24M |
| Float | 43.43M |
| Short Ratio | 10.72 |
| % Held by Insiders | 2.85% |
| % Held by Institutions | 105.62% |
| Shares Short | 10.9M |
| Short % of Float | 22.10% |
| Short % of Shares Outstanding | 19.32% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -208.56% |
| Operating Margin (ttm) | -222.71% |
| Gross Margin | -100.38% |
| EBITDA Margin | -217.52% |
Management Effectiveness
| Return on Assets (ttm) | -31.36% |
| Return on Equity (ttm) | -56.68% |
Income Statement
| Revenue (ttm) | 96.06M USD |
| Revenue Per Share (ttm) | 1.4 USD |
| Quarterly Revenue Growth (yoy) | 4505.59% |
| Gross Profit (ttm) | -96432000 USD |
| EBITDA | -208967008 USD |
| Net Income Avi to Common (ttm) | -200354000 USD |
| Diluted EPS (ttm) | -2.63 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 306.99M USD |
| Total Cash Per Share (mrq) | 5.45 USD |
| Total Debt (mrq) | 38.41M USD |
| Total Debt/Equity (mrq) | 11.37 USD |
| Current Ratio (mrq) | 6.151 |
| Book Value Per Share (mrq) | 7.383 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -166284000 USD |
| Levered Free Cash Flow (ttm) | -95916872 USD |
Profile of 4D Molecular Therapeutics
| Country | United States |
| State | CA |
| City | EmeryVille |
| Address | 5858 Horton Street |
| ZIP | 94608 |
| Phone | 510 505 2680 |
| Website | https://www.4dmoleculartherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 196 |
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Q&A For 4D Molecular Therapeutics Stock
What is a current FDMT stock price?
4D Molecular Therapeutics FDMT stock price today per share is 12.23 USD.
How to purchase 4D Molecular Therapeutics stock?
You can buy FDMT shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for 4D Molecular Therapeutics?
The stock symbol or ticker of 4D Molecular Therapeutics is FDMT.
Which industry does the 4D Molecular Therapeutics company belong to?
The 4D Molecular Therapeutics industry is Biotechnology.
How many shares does 4D Molecular Therapeutics have in circulation?
The max supply of 4D Molecular Therapeutics shares is 56.38M.
What is 4D Molecular Therapeutics Price to Earnings Ratio (PE Ratio)?
4D Molecular Therapeutics PE Ratio is now.
What was 4D Molecular Therapeutics earnings per share over the trailing 12 months (TTM)?
4D Molecular Therapeutics EPS is -2.7 USD over the trailing 12 months.
Which sector does the 4D Molecular Therapeutics company belong to?
The 4D Molecular Therapeutics sector is Healthcare.
4D Molecular Therapeutics FDMT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25136.27 USD — |
-0.91
|
7.74B USD — | 24872.41 USD — | 25423.09 USD — | — - | 7.74B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12378.66 USD — |
-0.9
|
— — | 12248.6 USD — | 12520.36 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7211.27 USD — |
-0.5
|
— — | 7149.19 USD — | 7238.9 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1368.29 USD — |
-0.34
|
— — | 1358.68 USD — | 1373.65 USD — | — - | — — |
